| This report contains COVID-19 specific updates.
Head and Neck Cancer Therapeutics: Global Markets
Report Highlights
The global market for head and neck cancer therapeutics is estimated to increase from $1.7 billion in 2022 to $2.6 billion by 2027, at a compound annual growth rate (CAGR) of 8.5% from 2022 through 2027.
Report Includes
- 64 data tables and 17 additional tables
- A comprehensive overview of the global markets for head and neck cancer therapeutics within the industry
- Analyses of the global market trends, with historic market revenue data for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation and forecast the actual market size for head and neck cancer therapeutics, and corresponding market share analysis by diagnostic method, treatment type, disease indication, route of administration, therapeutic class, end-user, and region
- Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on COVID-19 impact on the head and neck cancer therapeutics market
- Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on new products development, regulatory scenario, and reimbursement and pricing factors
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, and major types of end-user markets
- Market share analysis of the key market participants in the global pharmaceuticals industry, their research priorities, product portfolios, pipeline products, and company competitive landscape
- Descriptive company profiles of the leading global players, including AstraZeneca plc, Bristol-Myers Squibb, Eli Lilly and Co., Sanofi S.A., Merck & Co., and Pfizer Inc.
Report Scope
This report aims to provide a comprehensive study of the global market for head and neck cancer therapeutics, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding head and neck cancer therapeutic drugs.
An in-depth analysis of the global head and neck cancer therapeutics market includes historical data and market projections on sales by type of diagnostic method, treatment type, disease indication, route of administration, therapeutic class, and end user. It describes the different types of head and neck cancers (lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer) and their current and historical market revenues. This report also categorizes the global head and neck cancer therapeutics market based on the route of administration (injectable and oral).
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market shares. The report also discusses pipeline analysis and the new regulatory landscape of the drugs marketed.
Analyst Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Synopsis
| Report Metrics | Details | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2021 | |||||||||
| Forecast period considered | 2022-2027 | |||||||||
| Base year market size | $1.6 billion | |||||||||
| Market size forecast | $2.5 billion | |||||||||
| Growth rate | CAGR of 8.5% from 2022 to 2027 | |||||||||
| Units considered | $ Millions | |||||||||
| Segments covered | Diagnostic Method, Treatment Type, Disease Indication, Route of Administration, Therapeutic Class, End User | |||||||||
| Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | |||||||||
| Countries covered | United States, Canada, Germany, France, U.K., Spain, Italy, Sweden, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Russia, Japan, China, India, Australia, South Korea, Singapore, New Zealand, Taiwan, Malaysia, Thailand, Philippines, Indonesia, Latin America, Middle East and Africa | |||||||||
| Key Market Drivers |
|
|||||||||
| Companies studied |
|